About fitusiran
Antithrombin-lowering RNA interference medicine
Used for
- Routine prevention of bleeding episodes in adults and children aged 12 years or older with hemophilia A or B, with or without inhibitors.
Usual adult dose
Subcutaneous injection every two months, adjusted using antithrombin activity and product-specific dosing instructions.
Usual dose in children
For ages 12 years or older: subcutaneous injection every two months, adjusted using antithrombin activity and product-specific dosing instructions.
Common side effects
- Injection-site reactions
- Headache
- Increased liver enzymes
- Blood clots
Important warnings
- Can cause serious blood clots; dosing and antithrombin monitoring are essential.
- Liver injury is possible; liver tests are required.
- Use factor concentrates or bypassing agents only as directed, because excessive amounts increase clot risk.
- Not for treating an active bleed.
Pregnancy
Human pregnancy information is limited. Use only if the potential benefit justifies potential fetal risk.
Breastfeeding
It is unknown whether fitusiran passes into breast milk; effects on a nursing infant are uncertain.
Interactions
- Factor VIII or IX concentrates and bypassing agents may increase clot risk if used excessively.
- Avoid combining with other medicines that lower antithrombin unless specifically directed.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.